Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 9/20 | 0.57 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11996666 | 0.82 | KCNN4 (0.44) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL28240314 | 0.80 | MAPT (0.55) | KCNN4KIF11MAPTHTTKMT2A | |
| SCHEMBL2634475 | 0.74 | KCNN4 (0.63) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL2338402 | 0.73 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL16892955 | 0.73 | KCNN4 (0.68) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL5795295 | 0.72 | KCNN4 (0.61) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL10885402 | 0.72 | KCNN4 (0.61) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL30753741 | 0.72 | KCNN4 (0.41) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL11091284 | 0.71 | KCNN4 (0.65) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 | |
| SCHEMBL10809968 | 0.71 | KCNN4 (0.65) | KCNN4KCNE1KCNQ1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455549-B2 | Carbonylamino derivatives useful for the treatment of certain inflammatory disorders | ANIONA APS (DK) | 2013-06-04 | — | — | US | claimed |
| EP-1911740-B1 | POTASSIUM CHANNEL MODULATORS | NEUROSEARCH AS (DK) | 2013-02-27 | — | — | EP | claimed |
| US-20110124735-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEURO SEARCH A/S (DK) | 2011-05-26 | — | — | US | claimed |
| EP-2192896-B1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | NEUROSEARCH AS (DK) | 2011-01-12 | — | — | EP | claimed |
| EP-2192896-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEUROSEARCH A/S (DK) | 2010-06-09 | — | — | EP | claimed |
| WO-2009027292-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NEUROSEARCH A/S (DK) | 2009-03-05 | — | — | WO | claimed |
| EP-1911740-A1 | POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2008-04-16 | — | — | EP | claimed |
| US-20070161607-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2007-07-12 | — | — | US | claimed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | claimed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | claimed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | claimed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-8455549-B2 | Carbonylamino derivatives useful for the treatment of certain inflammatory disorders | ANIONA APS (DK) | 2013-06-04 | — | — | US | disclosed |
| US-7208527-B2 | Potassium channel modulators | POSEIDON PHARMACEUTICALS A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-20050009816-A1 | Potassium channel modulators | SANIONA A/S (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1465863-A1 | POTASSIUM CHANNEL MODULATORS | Poseidon Pharmaceuticals A/S (DK) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003059873-A1 | POTASSIUM CHANNEL MODULATORS | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009816-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885 |
| US-20070161607-A1 | Potassium channel modulators | KCNC1, KCNQ1, KCNA1 | KCNN4 48/4885KCNE1 29/4885KCNQ1 2/4885 |
| US-20110124735-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR THE TREATMENT OF CERTAIN INFLAMMATORY DISORDERS | NFKBIA, TNF, LTC4S | KCNN4 4646/4885KCNE1 4420/4885KCNQ1 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.